Fecal Proteolytic Bacteria and Staphylococcal Superantigens are Associated with Abdominal Pain Severity in Irritable Bowel Syndrome.


Journal

The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030

Informations de publication

Date de publication:
21 Aug 2024
Historique:
received: 04 06 2024
accepted: 30 07 2024
medline: 21 8 2024
pubmed: 21 8 2024
entrez: 21 8 2024
Statut: aheadofprint

Résumé

Changes in the composition of the gut microbiota have been associated with the development of Irritable Bowel Syndrome (IBS). However, to what extent specific bacterial species relate to clinical symptoms remains poorly characterized. We investigated the clinical relevance of bacterial species linked with increased proteolytic activity, histamine production, and superantigen (SAg) production in IBS patients. Fecal (n=309) and nasal (n=214) samples were collected from patients with IBS and healthy volunteers (HV). Clinical symptoms and gut transit time were evaluated. Bacterial abundance in feces and nasal swabs as well as fecal trypsin-like activity were assessed. The percentage of fecal samples containing Staphylococcus aureus was significantly higher in IBS compared to HV. Forty-nine % of S. aureus-positive fecal samples from patients with IBS were also positive for SAgs, compared to 12% of HV. Patients with IBS and positive fecal SAg-producing S. aureus reported higher pain scores than those without S. aureus. Moreover, increased fecal proteolytic activity was associated with abdominal pain. Fecal abundance of Paraprevotella clara and Alistipes putredinis was significantly decreased in IBS, particularly in samples with higher proteolytic activity. Patients with lower Alistipes putredinis or Faecalibacterium prausnitzii abundance reported more severe abdominal pain. In keeping with our preclinical findings, we show that increased presence of SAg-producing S. aureus in fecal samples of patients with IBS is associated with increased levels of abdominal pain. We also show that increased fecal proteolytic activity is associated with increased abdominal pain in patients with IBS.

Identifiants

pubmed: 39166748
doi: 10.14309/ajg.0000000000003042
pii: 00000434-990000000-01309
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Onderzoeksraad, KU Leuven
ID : C14/18/086
Organisme : Fonds Wetenschappelijk Onderzoek
ID : W001620N

Informations de copyright

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.

Auteurs

Runze Quan (R)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Lisse Decraecker (L)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Iris Appeltans (I)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

María Cuende-Estévez (M)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Samuel Van Remoortel (S)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Javier Aguilera-Lizarraga (J)

Laboratory of Sensory Neurophysiology and Pain, Department of Pharmacology, University of Cambridge, Tennis Court Road, Cambridge, CB2 1PD, United Kingdom.

Zheng Wang (Z)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Gareth Hicks (G)

Solent Therapeutics, Rancho Santa Fe, California, United States of America.

Jill Wykosky (J)

Solent Therapeutics, Rancho Santa Fe, California, United States of America.

Peter McLean (P)

Solent Therapeutics, Rancho Santa Fe, California, United States of America.

Alexandre Denadai-Souza (A)

Laboratory of Mucosal Biology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Hind Hussein (H)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Guy E Boeckxstaens (GE)

Center for Intestinal Neuroimmune Interactions, Translational Research Center for Gastrointestinal Disorders (TARGID), KU Leuven Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, 3000, Belgium.

Classifications MeSH